Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENERIC DRUG MARKET SHARE RISE MAY NOT RESTRAIN PRICE INCREASES

Executive Summary

GENERIC DRUG MARKET SHARE RISE MAY NOT RESTRAIN PRICE INCREASES for brand name drugs subject to state generic substitution laws, according to a recently released survey by several Federal Trade Commission staff members. The survey, for example, found that between 1980-1984, for the 10 top substitution drugs of 1980, the prices of the brand name products "rose by about the same amount (36.2%) as the average of all drugs. Thus, whether an increase in generic market share itself can force down the mfr.'s price of the leading brand and whether the increase in generic market shares in individual drug entities brought about by substitution will be enough to accomplish this is still an open question." In their report, entitled Generic Substitution and Prescription Drug Prices: Economic Effects of State Drug Product Selection Laws, authors Alison Masson and Robert L. Steiner conclude that: "drug product selection laws have reduced retail prescription prices by increasing the market share of generics, but not at the scale hoped for by some advocates of the laws." The 1984 figures were based on an extrapolation from 1980 data, estimated increases in number and average price of prescriptions, and estimated doubling of the substitution rate. Results showed generic purchases saved consumers at least $130 million in 1984, but the savings represented generic substitution "on probably less than a fifth of all eligible prescriptions." The "vivid result," said the authors, was "the very modest amount of substitution occurring in most states and most drugs." They found that generic prescribing by physicians accounted for nearly three-quarters (71.7%) of the overall generic market share. Therefore, "since a change in the amount of generic prescribing translates almost directly into generic market share, whatever determines differences in generic prescribing is responsible for a good portion of any differences in average retail prescription drug prices." Masson and Steiner found that seven drugs accounted for more than half of all generically dispensed prescriptions. The seven drugs (quinidine sulfate, nitroglycerin, tetracycline, ampicillin, penicillin VK, hydrochlorothiazide, and amoxicillin) are prescribed frequently and usually by generic name. The format of the physician's prescription pad, often designed by substitution laws, was also shown to be a significant factor in generic prescribing. "In particular," said Masson and Steiner, "if prohibition of substitution is made especially convenient for the physician, substitution occurs less frequently because, presumably, physicians prohibit it more often." Questioning "Why Isn't Substitution Prevalent?" the study cited "consumer resistance." The authors referred to a 1983 FDA survey showing that only 3-6% of patients ask their doctors how to take the drug prescribed, precautions, or side effects. "If patients fail to ask even about these behavioral and health issues, it seems unlikely that they will challenge the doctor's choice of brand," speculated Masson and Steiner. The FTC report predicted the potential influence of drug product substitution laws, saying, "as consumers and health professionals continue to garner experience with generics, they are likely to find substitution increasingly acceptable."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel